Parallel Advisors’s CorMedix CRMD Stock Holding History

Parallel Advisors’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$424	Buy	+54	New	+$427	﹤0.01%	3809
2026 Q1	–	Sell	-1,419	Closed	-$16.5K	–	3862
2025 Q4	$16.5K	Buy	+1,419	New	+$15.7K	﹤0.01%	2390
2024 Q3	–	Sell	-249	Closed	-$1.08K	–	3411
2024 Q2	$1.08K	Buy	+249	New	+$1.26K	﹤0.01%	2938
2021 Q1	–	Sell	-3,475	Closed	-$26K	–	2807
2020 Q4	$26K	Sell	3,475 -272	-7%	-$1.85K	﹤0.01%	1373
2020 Q3	$23K	Hold	3,747	–	–	﹤0.01%	1382
2020 Q2	$23K	Hold	3,747	–	–	﹤0.01%	1348
2020 Q1	$13K	Hold	3,747	–	–	﹤0.01%	1482
2019 Q4	$27K	Hold	3,747	–	–	﹤0.01%	1262
2019 Q3	$24K	Buy	+3,747	New	+$31.5K	﹤0.01%	1273

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Parallel Advisors's CRMD Position: Q2 2026 in Review

Parallel Advisors opened a new position in CorMedix (CRMD) in Q2 2026: 54 shares worth $424. The stake represents ﹤0.01% of the portfolio and ranks #3809 among its holdings. This is a return to the name: Parallel Advisors previously reported a position in CRMD as recently as Q4 2025.

Parallel Advisors first reported a position in CRMD in Q3 2019 and has held it in 9 quarters since. The position peaked at $27K in Q4 2019. 194 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

Parallel Advisors held 54 shares of CorMedix worth $424 as of Q2 2026.
CorMedix was a new Parallel Advisors position in Q2 2026.
CorMedix made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3809 holding.
Parallel Advisors first reported a position in CorMedix in Q3 2019 and has held it in 9 quarters since.
Parallel Advisors's CorMedix position peaked at $27K in Q4 2019.
194 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.